📇 Rhumatologue · CREUTZWALD · (57) · Libéral

M EMMANUEL BERGOT

Pourquoi vous devez consulter ce praticien

3 raisons identifiées

Auteur de référence en rhumatologie
28 articles scientifiques publiés — un praticien à la pointe de la recherche
Encadrant universitaire
Forme la prochaine génération de rhumatologues (2 thèses dirigées)
Délais de RDV courts dans la région
87.3 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 CREUTZWALD (57)LibéralRPPS 10001248417

Enseignement

14ans d'exercice (thèse 2012)

📊 Reconnaissance scientifique : 38/100📝 274 articles publiés🇫🇷 Publications académiques françaises (8)🎓 2 thèses dirigées

✨ Génération du profil synthétique IA en cours…

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series

Annals of the rheumatic diseases · 2020

📚 162 citations🎯 RCR 8.23Top 4% NIH

Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension

American journal of respiratory and critical care medicine · 2021

📚 161 citations🎯 RCR 11.99Top 2% NIH🔓 Open Access

Lire l'abstract Crossref ↓

Abstract Rationale The relationship between the initial treatment strategy and survival in pulmonary arterial hypertension (PAH) remains uncertain. Objectives To evaluate the long-term survival of patients with PAH categorized according to the initial treatment strategy. Methods A retrospective analysis of incident patients with idiopathic, heritable, or anorexigen-induced PAH enrolled in the French Pulmonary Hypertension Registry (January 2006 to December 2018) was conducted. Survival was assessed according to the initial strategy: monotherapy, dual therapy, or triple-combination therapy (two oral medications and a parenteral prostacyclin). Measurements and Main Results Among 1,611 enrolled patients, 984 were initiated on monotherapy, 551 were initiated on dual therapy, and 76 were initiated on triple therapy. The triple-combination group was younger and had fewer comorbidities but had a higher mortality risk. The survival rate was higher with the use of triple therapy (91% at 5 yr) as compared with dual therapy or monotherapy (both 61% at 5 yr) (P &lt; 0.001). Propensity score matching of age, sex, and pulmonary vascular resistance also showed significant differences between triple therapy and dual therapy (10-yr survival, 85% vs. 65%). In high-risk patients (n = 243), the survival rate was higher with triple therapy than with monotherapy or dual therapy, whereas there was no difference between monotherapy and double therapy. In intermediate-risk patients (n = 1,134), survival improved with an increasing number of therapies. In multivariable Cox regression, triple therapy was independently associated with a lower risk of death (hazard ratio, 0.29; 95% confidence interval, 0.11–0.80; P = 0.017). Among the 148 patients initiated on a parenteral prostacyclin, those on triple therapy had a higher survival rate than those on monotherapy or dual therapy. Conclusions Initial triple-combination therapy that includes parenteral prostacyclin seems to be associated with a higher survival rate in PAH, particularly in the youngest high-risk patients.

Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet. Respiratory medicine · 2022

📚 89 citations🎯 RCR 9.10Top 3% NIH🩺 Clinique

Cookies & analyse de trafic

M EMMANUEL BERGOT

Pourquoi vous devez consulter ce praticien

Thèses universitaires

Direction de thèses

Activité de recherche & publications

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (28) — classées par pathologie

Transversal18

Revue générale3

Essai clinique2

Case report / série1

Corticothérapie1

Économie santé1

Génétique1

Vraie vie / RWE1

Datasets & protocoles partagés

Partager cette fiche